NASDAQ:DYN Dyne Therapeutics Q3 2026 Earnings Results & Report $18.54 +0.49 (+2.71%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$18.84 +0.31 (+1.65%) As of 07:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dyne Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$1.06 versus the -$0.9073 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call7:00 AM ET Dyne Therapeutics EPS ResultsActual EPS-$1.06Consensus EPS -$0.9073Beat/MissMissed by -$0.1527One Year Ago EPS-$0.76EPS Beat Rate4 of last 8 quartersDyne Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dyne Therapeutics Q3 2026 Earnings FAQ Did Dyne Therapeutics beat earnings estimates for Q3 2026? Dyne Therapeutics (NASDAQ:DYN) reported earnings of -$1.06 per share for Q3 2026, missing the consensus estimate of -$0.9073. The report was announced on Thursday, November 5, 2026. Dyne Therapeutics Earnings HeadlinesDyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights59 minutes ago | globenewswire.comDyne Therapeutics, Inc. (DYN) - What Are Brokerages Thinking About This Stock?November 5 at 2:29 AM | americanbankingnews.com$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get access to the same fund for less than $20.November 5 at 1:00 AM | The Oxford Club (Ad)Dyne Therapeutics (NASDAQ:DYN) Stock Gets Downgrade from OppenheimerOctober 30, 2026 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down After Analyst DowngradeOctober 30, 2026 | americanbankingnews.comOppenheimer Downgrades Dyne Therapeutics to Perform From Outperform, $15 Price TargetOctober 28, 2026 | marketscreener.comMSee More Dyne Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email. Email Address About Dyne TherapeuticsDyne Therapeutics (NASDAQ:DYN) is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge. Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue. Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping. The company was founded in 2018 and is headquartered in Waltham, Massachusetts. Dyne is led by Chief Executive Officer John Cox and serves patients through its global clinical-development programs.View Dyne Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it Simple Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
